MGTX Nasdaq Biological Products, (No Diagnostic Substances) Financials FY2017βFY2025
MeiraGTx Holdings plc had $81.4M of revenue in fiscal 2025, up 144.6% on the year before. Over five years, revenue changed +39.2% a year on average.
Last close Β· Oct 23, 2026
$9.21
5.7%Hi! I read MeiraGTx Holdings plcβs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
+144.6%
Yes. Sales grew 144.6% last year.
Does it make a profit?
β140.3%
No. It lost money last year.
Does profit turn into cash?
β61.7%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 7
Weak. It passes 3 of 7 health tests.
How is the share priced?
13.0x
One share costs 13.0 times its yearly profit per share.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days MeiraGTx Holdings plc did it, and the next one. Share prices often move a lot on those days.
Next results
November 12, 2026
Thursday Β· in 17 days
| Date | Results for | Time | Source |
|---|---|---|---|
| Aug 13, 2026 | Q2 '26 | Before the market opens | 8-K β |
| May 14, 2026 | Q1 '26 | Before the market opens | 8-K β |
| Mar 25, 2026 | Q4 '25 | Time not announced | 8-K β |
| Nov 13, 2025 | Q3 '25 | Before the market opens | 8-K β |
| Aug 14, 2025 | Q2 '25 | Before the market opens | 8-K β |
| May 13, 2025 | Q1 '25 | Before the market opens | 8-K β |
| Mar 9, 2025 | Q4 '24 | Time not announced | 8-K β |
| Nov 13, 2024 | Q3 '24 | Before the market opens | 8-K β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· MeiraGTx Holdings plc had $81.4M of revenue in fiscal 2025, up 144.6% on the year before. Over five years, revenue changed +39.2% a year on average. Its operating margin was β130.2%, up 363.2Β pts: of every 100 in sales, about β130 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· MeiraGTx Holdings plc lost $114M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$50.2M in fiscal 2025, β61.7% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
Cash, debt and the ratios that show how comfortably MeiraGTx Holdings plc can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $138M | $116M | $130M | $104M | $65.9M |
| Interest coverage | β252.6x | β23.5x | β10.3x | β12.4x | β8.7x |
| Current ratio | 2.7x | 1.9x | 2.4x | 2.0x | 0.7x |
| Quick ratio | 2.7x | 1.9x | 2.4x | 2.0x | 0.7x |
| Total assets | $320M | $318M | $327M | $270M | $244M |
| Total liabilities | $135M | $200M | $189M | $202M | $250M |
| Shareholders' equity | $185M | $118M | $138M | $67.8M | β$5.8M |
| Net debt (β = net cash) | β | β | β | β | β |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· MeiraGTx Holdings plc passes 3 of 7 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | β / 6 | β / 6 | 2 / 7 | 2 / 7 | 1 / 7 | 2 / 7 | 2 / 7 | 3 / 7 |
| Accruals ratio | β50.2% | β39.1% | β35.5% | 1.7% | β20.2% | β17.7% | 6.6% | β14.5% | β26.4% |
| Altman Z'' | β21.28 | β1.03 | 2.70 | 2.45 | β1.19 | β5.17 | β5.72 | β10.70 | β14.65 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Revenue | β | β | $13.3M | $15.6M | $37.7M | $15.9M | $14.0M | $33.3M | $81.4M |
| Research and development | $22.4M | $33.6M | $24.9M | $33.9M | $66.7M | $85.7M | $104M | $119M | $130M |
| Operating income | β$31.7M | β$78.1M | β$58.3M | β$62.6M | β$72.8M | β$116M | β$137M | β$164M | β$106M |
| Interest expense | $0.0M | $0.0M | $0.0M | $0.1M | $0.3M | $4.9M | $13.2M | $13.3M | $12.2M |
| Pretax income | β$31.0M | β$83.3M | β$54.7M | β$58.0M | β$79.6M | β$130M | β$84.0M | β$148M | β$114M |
| Income tax | $0.0M | β$0.5M | $0.0M | $0.0M | $0.0M | β | $0.0M | $0.0M | $0.0M |
| Net income | β$31.0M | β$82.9M | β$54.7M | β$58.0M | β$79.6M | β$130M | β$84.0M | β$148M | β$114M |
| Net income to common | β$31.9M | β$84.7M | β$54.7M | β$58.0M | β$79.6M | β$130M | β$84.0M | β$148M | β$114M |
| Diluted EPS | β$3.72 | β$4.47 | β$1.65 | β$1.54 | β$1.80 | β$2.87 | β$1.49 | β$2.12 | β$1.42 |
| Diluted shares | 0.01B | 0.02B | 0.03B | 0.04B | 0.04B | 0.05B | 0.06B | 0.07B | 0.08B |
| Cash flow | |||||||||
| Cash from operations | β$18.1M | β$58.9M | $20.0M | β$64.0M | β$10.5M | β$73.1M | β$105M | β$104M | β$46.4M |
| Capital expenditure | $10.5M | $11.3M | $9.0M | $20.9M | $46.4M | $45.0M | $20.2M | $5.0M | $3.8M |
| Free cash flow | β$28.6M | β$70.1M | $11.1M | β$84.9M | β$56.9M | β$118M | β$126M | β$109M | β$50.2M |
| Depreciation and amortization | $0.7M | $2.1M | $2.2M | $4.2M | $7.9M | $8.7M | $13.7M | $12.8M | $12.5M |
| Stock-based compensation | $3.0M | $17.9M | $15.9M | $18.4M | $20.8M | $28.6M | $27.7M | $25.2M | $22.1M |
| Balance sheet | |||||||||
| Cash and short-term investments | $8.5M | $68.1M | $227M | $210M | $138M | $116M | $130M | $104M | $65.9M |
| Finance lease liabilities | β | β | $0.1M | $0.0M | $0.0M | β | β | β | $0.1M |
| Current assets | $11.5M | $74.7M | $269M | $273M | $183M | $154M | $160M | $124M | $91.8M |
| Current liabilities | $21.4M | $15.5M | $49.2M | $54.1M | $68.1M | $82.1M | $67.1M | $60.8M | $123M |
| Inventory | β | β | β | β | β | β | β | $0.4M | β |
| Property and equipment, net | $14.3M | $22.0M | $23.9M | $44.0M | $75.9M | $109M | $116M | $103M | $105M |
| Intangible assets | β | β | $0.0M | $2.1M | $1.8M | $1.3M | $1.1M | $0.8M | $0.6M |
| Total assets | $25.9M | $96.9M | $324M | $364M | $320M | $318M | $327M | $270M | $244M |
| Total liabilities | $21.9M | $15.8M | $133M | $125M | $135M | $200M | $189M | $202M | $250M |
| Shareholders' equity | β$47.4M | $81.1M | $191M | $239M | $185M | $118M | $138M | $67.8M | β$5.8M |
| Margins | |||||||||
| Operating margin | β | β | β438.4% | β401.9% | β193.0% | β730.9% | β977.8% | β493.4% | β130.2% |
| EBITDA margin | β | β | β421.5% | β375.1% | β172.1% | β676.1% | β879.9% | β454.9% | β114.8% |
| Net margin | β | β | β411.9% | β372.6% | β211.0% | β814.2% | β599.5% | β444.1% | β140.3% |
| FCF margin | β | β | 83.2% | β545.5% | β150.9% | β741.6% | β895.6% | β328.9% | β61.7% |
| Returns | |||||||||
| Return on capital employed | β711.6% | β96.0% | β21.2% | β20.2% | β28.9% | β49.3% | β52.8% | β78.6% | β86.9% |
| Return on equity | β | β491.9% | β40.3% | β27.0% | β37.5% | β85.5% | β65.7% | β143.5% | β368.2% |
| Return on assets | β120.1% | β135.0% | β26.0% | β16.9% | β23.3% | β40.6% | β26.1% | β49.6% | β44.4% |
| Return on tangible equity | β | β104.5% | β28.7% | β24.5% | β43.3% | β111.4% | β61.3% | β220.6% | β |
| Growth | |||||||||
| Revenue growth | β | β | β | 17.1% | 142.2% | β57.8% | β12.0% | 137.4% | 144.6% |
| FCF growth | β | β | β | β867.2% | β | β | β | β | β |
| Share count change | β | 121.0% | 75.0% | 13.8% | 17.0% | 2.4% | 25.0% | 23.6% | 15.2% |
| Financial health | |||||||||
| Interest coverage | β738.6x | β2,338.4x | β1,198.9x | β450.0x | β252.6x | β23.5x | β10.3x | β12.4x | β8.7x |
| Current ratio | 0.5x | 4.8x | 5.5x | 5.0x | 2.7x | 1.9x | 2.4x | 2.0x | 0.7x |
| Quick ratio | 0.5x | 4.8x | 5.5x | 5.0x | 2.7x | 1.9x | 2.4x | 2.0x | 0.7x |
| Capital allocation | |||||||||
| Capex / revenue | β | β | 67.6% | 134.4% | 122.9% | 282.4% | 143.9% | 14.9% | 4.7% |
| Stock comp / revenue | β | β | 119.8% | 118.3% | 55.1% | 179.8% | 197.7% | 75.7% | 27.2% |
| Quality scores | |||||||||
| Piotroski F-score | β | β | β | 2.0 | 2.0 | 1.0 | 2.0 | 2.0 | 3.0 |
| Altman Z'' | β21.3 | β1.0 | 2.7 | 2.4 | β1.2 | β5.2 | β5.7 | β10.7 | β14.7 |
| Accruals ratio | β50.2% | β39.1% | β35.5% | 1.7% | β20.2% | β17.7% | 6.6% | β14.5% | β26.4% |
Source: SEC EDGAR XBRL filings (CIK 0001735438). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
